BDSX — Biodesix, Inc.

Summary of Biodesix Q3 2025 Earnings Call

1. Key Financial Results and Metrics

• Total Revenue: $21.8 million, a 20% increase year-over-year.
• Lung Diagnostic Testing Revenue: $19.8 million from approximately 15,700 tests, reflecting 13% growth in test volumes and 16% growth in revenue compared to Q3 2024.
• Gross Margin: Improved to 81%, up 400 basis points from 77% in Q3 2024.
• Net Loss: $8.7 million, an improvement of 15% year-over-year.
• Adjusted EBITDA: Loss of $4.6 million, an 18% improvement year-over-year.
• Cash Position: $16.6 million in unrestricted cash and cash equivalents.

2. Strategic Updates and Business Highlights

• Sales Force Expansion: Increased from 65 to 85 sales representatives, with plans to reach 93-97 in Q4 2025.
• Primary Care Strategy: Significant growth in test orders from primary care, increasing from 4% to 11% of total tests ordered since implementing a new sales strategy.
• Clinical Evidence: Presented interim data from the CLARIFY study at the CHEST conference, reinforcing the utility of Nodify testing in real-world settings.
• Development Services Revenue: Grew 97% year-over-year to $1.9 million, with $12.9 million under contract, an all-time high.

3. Forward Guidance and Outlook

• Revenue Guidance: Increased for 2025 to a range of $84 million to $86 million.
• Adjusted EBITDA: Expected to achieve positivity in Q4 2025, supported by strong gross margins and effective sales expansion.

4. Bad News, Challenges, or Points of Concern

• Medicare Advantage Claims: While one major plan resumed payments, there are ongoing efforts to collect on older claims that were not recognized as revenue.
• Competitive Pressures: The lung diagnostic space remains competitive, with new entrants and tests potentially impacting market dynamics.
• Operational Costs: Despite a decrease in operating expenses quarter-over-quarter, the company faces ongoing supply cost pressures and macroeconomic uncertainties.

5. Notable Q&A Insights

• Primary Care Expansion: The success of the primary care strategy is being validated through increased test adoption and earlier cancer detection reported by physicians.
• Sales Rep Productivity: The company aims to return to a productivity target of $1 million per sales rep, with consistent ramp-up observed in new hires.
• Capital Needs: Management expressed confidence in reaching cash flow breakeven based on current business growth, despite utilizing some of the ATM facility in Q3 to manage accounts receivable.

Overall, Biodesix demonstrated strong growth in revenue and operational improvements in Q3 2025, while also navigating challenges related to claims processing and competitive pressures in the diagnostics market. The company is optimistic about achieving profitability in the near term and expanding its market presence through strategic initiatives.